These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21138843)

  • 21. Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice.
    Sockolosky JT; Kivimäe S; Szoka FC
    PLoS One; 2014; 9(7):e102566. PubMed ID: 25057984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
    Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
    J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.
    Sockolosky JT; Tiffany MR; Szoka FC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16095-100. PubMed ID: 22991460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
    Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
    Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.
    Chaudhury C; Mehnaz S; Robinson JM; Hayton WL; Pearl DK; Roopenian DC; Anderson CL
    J Exp Med; 2003 Feb; 197(3):315-22. PubMed ID: 12566415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential trafficking of albumin and IgG facilitated by the neonatal Fc receptor in podocytes in vitro and in vivo.
    Dylewski J; Dobrinskikh E; Lewis L; Tonsawan P; Miyazaki M; Jat PS; Blaine J
    PLoS One; 2019; 14(2):e0209732. PubMed ID: 30811433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.
    Kenanova VE; Olafsen T; Salazar FB; Williams LE; Knowles S; Wu AM
    Protein Eng Des Sel; 2010 Oct; 23(10):789-98. PubMed ID: 20802234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neonatal Fc receptor, key control of immunoglobulins biodistribution].
    Magdelaine-Beuzelin C; Ohresser M; Watier H
    Med Sci (Paris); 2009 Dec; 25(12):1053-6. PubMed ID: 20035678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
    Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
    Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.
    Sand KM; Dalhus B; Christianson GJ; Bern M; Foss S; Cameron J; Sleep D; Bjørås M; Roopenian DC; Sandlie I; Andersen JT
    J Biol Chem; 2014 Jun; 289(24):17228-39. PubMed ID: 24764301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of the FcRn:IgG protein-protein interaction.
    Low SC; Mezo AR
    AAPS J; 2009 Sep; 11(3):432-4. PubMed ID: 19499344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.
    Ma G; Crowley AR; Heyndrickx L; Rogiers I; Parthoens E; Van Santbergen J; Ober RJ; Bobkov V; de Haard H; Ulrichts P; Hofman E; Louagie E; Balbino B; Ward ES
    JCI Insight; 2024 May; 9(10):. PubMed ID: 38713534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.